French AI-powered radiography diagnostics specialist Gleamer SAS has raises €27m in Series B round to expand its portfolio and accelerate its expansion.
Tag Archive for: financing
French cell and gene therapy manufacturing specialist Astraveus SAS had raises €16.5m in seed money to advance its automated, microfluidic Cell and Gene Therapy manufacturing platform.
Carbios SAS has announced a capital increase of around €122m that may grow up to €141m.
Bergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing.
,
Bristol-based eXmoor Pharma Ltd has completed a US$35m Series A financing to expand its cell and gene therapy manufacturing capabilities.
Leiden-based VarmX BV said it will use the €30m Series B2 money to complete the data required for IND approval of its lead candidate VMX-C001, a recombinante antidote to oral factor Xa inhibitors which are widely used to prevent blood clotting but can lead to dangerous bleeding episodes. The proceeds will also enable VarmX to scale manufacturing of VMX-C001 for its further clinical testing. The financing was led by Sound Bioventures the EIC Fund joining existing investors EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, InnovationQuarter, and Libertatis Ergo Holding.The Dutch company had already completed a €32m Series B financing in 2020.
VarmX has completed enrollment of patients into a first-in-human study, to demonstrate safety and provide clinical proof of principle of the compound. The company will present initial data at the International Society on Thrombosis and Haemostasis conference in Montreal (June 24-28, 2023). Full study results of the study that is set to enroll 88 patients will be available later this year.
VMX-C001 is a modified recombinant human blood clotting factor X derived from the Australian brown snake venome that enables blood to clot normally in the presence of synthetic factor Xa blood clotting inhibitors. About 2-3% of the annually 10 million patients that receive Factor Xa blood clotting blockers suffer from severe bleeds. VMX-C001 is set to facilitate the fast, safe and effective treatment of severe spontaneous bleeds in patients that are taking direct oral anticoagulant blood thinners (DOACs) and, in addtion, to enable patients on this class of blood thinners to undergo emergency surgery without the risk of bleeding associated with FXa DOACs.
The compound has the potential for a strong and differentiated profile, including universal and single dose reversal, ease-of-use and safety that supports emergency care use and it shows promise for applications in other indications.
Belgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic.
French pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.
Munich-based microbiome therapeutics specialist mbiomics GmbH has raised €13m in the first closing of Series A round led by MIG Capital.
With assets of €12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.